Listar por autor "Orpez, Teresa"
Mostrando ítems 1-7 de 7
-
Early development of anti-natalizumab antibodies in MS patients
Oliver-Martos, Begoña
; Órpez, Teresa; Urbaneja, Patricia; Maldonado-Sanchez, Rafael; Leyva-Fernández, Laura; Fernández Fernández, Óscar[et al.] (SpringerLink, 2013)
The purpose of this study is to monitor the development of anti-natalizumab antibodies to evaluate their first appearance in multiple sclerosis patients, since their presence has been associated with a reduction in the ... -
Gene expression in IFNß signalling pathway differs between monocytes, CD4 and CD8 T cells from MS patients
Oliver-Martos, Begoña; Órpez, Teresa; Pinto-Medel, Maria Jesús; Mayorga Mayorga, Cristobalina; García-León, Juan Antonio; Maldonado-Sanchez, Rafael; Suardíaz García, Margarita; Guerrero, Miguel; Luque, Gloria; Leyva-Fernández, Laura; Fernández Fernández, Óscar[et al.] (Elsevier, 2011)
IFNß exerts its activity through the interaction with IFNAR, through activation of the JAK/STAT pathway. We analyzed the changes in IFNAR1, IFNAR2, STAT1, STAT2, Tyk2, JAK1, IRF9 and MxA gene expressions after prolonged ... -
Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months
Oliver-Martos, Begoña; Fernández Fernández, Óscar; Órpez, Teresa; Alvarenga, Marcos Papais; Pinto-Medel, Mª Jesús; Guerrero, Miguel; León, Antonio; López-Madrona, José Carlos; Maldonado-Sánchez, Rafael; García-León, Juan Antonio; Luque, Gloria; Fernández Sánchez, Victoria Eugenia; Leyva-Fernández, Laura[et al.] (SAGE Journals, 2011)
Natalizumab is a monoclonal antibody shown to be highly effective in the treatment of relapsing–remitting multiple sclerosis (RRMS). Patients treated with natalizumab can develop antibodies directed against this agent that ... -
Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months.
Oliver-Martos, Begoña; Fernández, Óscar; Orpez, Teresa; Alvarenga, Marco Papais; Pinto-Medel, María Jesús; Guerrero, Miguel; León, Antonio; López-Madrona, José Carlos; Maldonado-Sánchez, Rafael; García-León, Juan Antonio; Luque, Gloria; Fernández, Victoria; Leyva-Fernández, Laura[et al.] (SAGE, 2011-03)
Natalizumab is a monoclonal antibody shown to be highly effective in the treatment of relapsing-remitting multiple sclerosis (RRMS). Patients treated with natalizumab can develop antibodies directed against this agent that ... -
Neutralizing antibodies against IFN beta in patients with multiple sclerosis: a comparative study of two cytopathic effect tests (CPE) for their detection
Oliver-Martos, Begoña; Orpez, Teresa; Mayorga Mayorga, Cristobalina; Leyva-Fernández, Laura; López-Gómez, Carlos; Marín, Carmen; Luque, Gloria; Fernández Fernández, Óscar[et al.] (Elsevier, 2009)
The purpose of this study is to monitor the development of anti-natalizumab antibodies to evaluate their first appearance in multiple sclerosis patients, since their presence has been associated with a reduction in the ... -
Recombinant soluble IFN receptor (sIFNAR2) exhibits intrinsic therapeutic efficacy in a murine model of Multiple Sclerosis
Suardíaz García, Margarita; Clemente, Diego; Marín Bañasco, Carmen; Órpez, Teresa; Hurtado-Guerrero, Isaac; Pavía-Molina, José; Pinto-Medel, Maria Jesús; De Castro, Fernando; Leyva-Fernández, Laura; Fernández Fernández, Óscar; Oliver-Martos, Begoña[et al.] (Elsevier, 2016)
Endogenous interferon beta (IFNβ) is an important cytokine involved in several chronic inflammatory diseases, such as Multiple Sclerosis (MS). In spite of the numerous therapeutic approaches available for MS patients, the ... -
The CD4+ T-cell subset lacking expression of the CD28 costimulatory molecule is expanded and shows a higher activation state in multiple sclerosis.
Pinto-Medel, María Jesús; García-León, Juan Antonio; Oliver-Martos, Begoña; López-Gómez, Carlos; Luque, Gloria; Arnáiz-Urrutia, Carlos; Órpez, Teresa; Marín-Bañasco, Carmen; Fernández Fernández, Óscar; Leyva-Fernández, Laura[et al.] (Elsevier, 2012-01-18)
Multiple sclerosis (MS) is a chronic debilitating disease, in which T-cells are considered to play a pivotal role. CD28 is the quintessential costimulatory molecule on T-cells and its expression declines progressively ...